Current Main Topics in Multiple Myeloma

• Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

  2020 Blood article Medicine Multiple Myeloma Research and Treatments Open access

  703

  citations
• Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

  2020 The Lancet Haematology article Medicine Multiple Myeloma Research and Treatments Open access cited by 2 patents

  384

  citations
• Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

  2021 The Lancet Oncology article Medicine Multiple Myeloma Research and Treatments Open access cited by 13 patents

  345

  citations
• Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

  2021 The Lancet Oncology article Medicine Multiple Myeloma Research and Treatments Open access

  182

  citations
• Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

  2022 The Lancet Haematology article Medicine Multiple Myeloma Research and Treatments

  160

  citations
• Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

  2020 Blood article Medicine Multiple Myeloma Research and Treatments

  24

  citations
• Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma

  2022 Blood article Medicine Multiple Myeloma Research and Treatments Open access

  17

  citations

7 results